AI Verdict
GMED has stronger fundamentals based on our AI analysis.
GNSS vs GMED Fundamental Comparison
| Metric | GNSS | GMED |
|---|---|---|
| Revenue | $17.1M | $2.9B |
| Net Income | $-817,000.0 | $537.9M |
| Net Margin | -4.8% | 18.3% |
| ROE | -45.2% | 11.8% |
| ROA | -1.2% | 10.1% |
| Current Ratio | 0.73x | 4.26x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-0.02 | $3.92 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
GNSS vs GMED: Frequently Asked Questions
Is GNSS or GMED a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), GMED has stronger fundamentals. GNSS is rated SELL (56% confidence) while GMED is rated BUY (78% confidence). This is not investment advice.
How does GNSS compare to GMED fundamentally?
Genasys Inc. has ROE of -45.2% vs GLOBUS MEDICAL INC's 11.8%. Net margins are -4.8% vs 18.3% respectively.
Which stock pays higher dividends, GNSS or GMED?
GNSS has a dividend yield of N/A or no dividend while GMED has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in GNSS or GMED for long term?
For long-term investing, consider that GNSS has SELL rating with 56% confidence, while GMED has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about GNSS vs GMED?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GNSS vs GMED, the AI consensus favors GMED based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.